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Abstract
Background: Many anticancer agents have poor water solubility and therefore the development
of novel delivery systems for such molecules has received significant attention. Nanocarriers show
great potential in delivering therapeutic agents into the targeted organs or cells and have recently
emerged as a promising approach to cancer treatments. The aim of this study was to prepare and
use poly-2-hydroxyethyl methacrylate (PHEMA) nanoparticles for the controlled release of the
anticancer drug doxorubicin.
Results: PHEMA nanoparticles have been synthesized and characterized using FTIR and scanning
electron microscopy (SEM), particle size analysis and surface charge measurements. We also
studied the effects of various parameters such as percent loading of drugs, chemical architecture
of the nanocarriers, pH, temperature and nature of the release media on the release profiles of the
drug. The chemical stability of doxorubicin in PBS was assessed at a range of pH.
Conclusion: Suspension polymerization of 2-hydroxyethyl methacrylate (HEMA) results in the
formation of swellable nanoparticles of defined composition. PHEMA nanoparticles can potentially
be used for the controlled release of the anticancer drug doxorubicin.
Background
The number of reported cases of cancer is steadily increas-
ing in both industrialised and developing countries. The
latest world cancer statistics indicate that the number of
new cancer cases will increase to more than 15 million in
2020 whereas another report issued by the World Health
organization says that there are over 10 million new cases
of cancer each year and over 6 million deaths annually are
caused by the disease [1]. In spite of the fact that signifi-
cant progress has been achieved in tumor biology, molec-
ular genetics and in the prevention, detection and
treatment of cancer over the last few years, adequate ther-
apy remains elusive due to late diagnosis, inadequate
strategies for addressing aggressive metastasis, and the
lack of clinical procedures overcoming multidrug resistant
(MDR) cancer [2]. The integration of nanotechnology and
medicine has the potential to uncover the structure and
function of biosystems at the nanoscale level. Nanobio-
technology may provides a reliable and effective tool to
treat diseases at a molecular scale. Nanobiotechnology
offers an unprecedented opportunity to rationalize deliv-
ery of drugs and genes to solid tumours following sys-
temic administration [3]. Examples of nanotechnologies
applied in pharmaceutical product development include
polymer-based nanoparticles, lipid-based nanoparticles
(liposomes, nanoemulsions, and solid-lipid nanoparti-
cles), self-assembling nanostructures such as micelles and
dendrimers-based nanostructures among others. In recent
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years, much research has gone into the characterisation of
nanoparticles and their biological effects and potential
applications. These include bottom-up and molecular
self-assembly, biological effects of naked nanoparticles
and nano-safety, drug encapsulation and nanotherapeu-
tics, and novel nanoparticles for use in microscopy, imag-
ing and diagnostics [4].
To be successful a cancer treatment approach needs to
overcome physiological barriers such as vascular endothe-
lial pores, heterogeneous blood supply, heterogeneous
architecture to name just a few [5], and and it strongly
depends on the method of delivery. In the past, many
anticancer drugs had only limited success and had major
adverse side effects [6,7]. Nanoparticles have attracted
considerable attention worldwide because of their unique
functional characters such as small particle size, high sta-
bility, lower toxicity, tuneable hydrophilic-hydrophobic
balance and the ability to bear surface features for target
specific localization, etc. Thus, polymeric nanoparticles
constitute a versatile drug delivery system [8], which can
potentially overcome physiological barriers, and carry the
drug to specific cells or intracellular compartments by pas-
sive or ligand-mediated targeting approaches [9]. The use
of some polymers also allows, at least in principle, to
achieve controlled release and the sustained drug levels
for longer periods of time. Numerous biodegradable pol-
ymeric nanoparticles made of natural polymers such as
proteins or polysaccharides have been tried for drug deliv-
ery and controlled drug release. More recently the focus of
such studies moved onto synthetic polymers, and much
progress have been achieved in this area. Recent examples
include, for example polycationic nanoparticles for
encapsulation and controlled release of amphotericin B
by Vieria and Carmona-Ribeiro [10]; or encapsulation of
curcumin for human cancer therapy by Maitra et al [11].
Ideally, a successful nanoparticulate system should have a
high drug loading capacity thereby reducing the quantity
of matrix material for administration. The drug may be
bound to the nanoparticles either (i) by polymerization in
the presence of drug in most cases in the form of solution
(incorporation method) or (ii) by absorbing/adsorbing
the drug after the formation of nanoparticles by incubat-
ing them in the drug solution. In the present work we set
to further investigate the latter method by studying swell-
ing and controlled release of antitumour drug doxoru-
bicin from synthetic PHEMA nanoparticles. PHEMA
attracted significant attention and is well documented in
the literature. Many useful properties which make PHEMA
attractive for a wide range of biomedical applications [12]
include high water content, low toxicity and tissue com-
patibility. PHEMA has been used in applications such as
soft contact lenses [13], drug delivery systems [14], kidney
dialysis membranes [15], artificial liver support systems
[16] and nerve guidance channels [17]. The presence of
polar groups of hydroxyl and carboxyl on each repeat unit
makes this polymer compatible with water and the hydro-
phobic -methyl groups of the backbone convey hydro-
lytic stability to the polymer and enhance mechanical
strength of the polymer matrix [18]. The drug chosen for
this study was doxorubicin hydrochloride, which belongs
to the family of anti-tumour drugs (Fig. 1). Doxorubicin
is a cytotoxic anthracycline antibiotic [19], it is widely
used in the treatment of non-Hodkin's lymphoma, acute
lymphoblastic leukemia, breast carcinomas and several
other types of cancer. We aimed to design a better PHEMA
nanoparticulate delivery system for clinical administra-
tion of doxorubicin to achieve higher therapeutic efficacy
and reduce side effects, with the overall aim to develop
effective oral chemotherapy system.
Results and Discussion
Preparation and characterization of Nanoparticles
The FTIR spectra of the pure drug (doxorubicin) and
loaded nanoparticles are shown in Fig. 2(a) and 2(b),
respectively. The IR spectra (b) of loaded nanoparticles
clearly indicate the presence of HEMA as evident from the
observed bands at 1728 cm-1 (C=O stretching), 1172 cm-1
(O-C-C stretching), 3556 cm-1 (O-H stretching), 2951 cm-
1 (asymmetric stretching of methylene group) and 1454
cm-1 (O-H bending) respectively. The spectra (b) also
mark the presence of drug (doxorubicin) as evident from
the observed bands at 1000-1260 cm-1 (C-O stretching of
alcohol) and 675-900 cm-1 (out of plane O-H bending).
The resemblance of spectra shown in Fig. 2(a) (the pure
drug) and in Fig. 2(b) (loaded nanoparticles) confirms
the presence of drug in the loaded nanoparticles.
Structure of drug Doxorubicin Figure 1
Structure of drug Doxorubicin. Chemical structure of 
anticancer drug [Doxorubicin].Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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The SEM image of nanoparticles is shown in Fig. 3(a),
which also reveals the morphology of PHEMA nanoparti-
cles. The size of nanoparticles was estimated using SEM
images. Under our experimental conditions it has been
shown to vary between 100 and 300 nm. The particle size
distribution curve of prepared nanoparticles is shown in
Fig. 3(b). The small (defined) size of the nanocarriers
results in the increased surface to volume ratio [20],
enhanced frictional forces as well as adsorption [21].
These properties allow nanoparticles to be held in suspen-
sion and largely define their biological fate, toxicity and
targeting ability, as well as drug loading potential, their
stability and drug release properties. The interaction of
nanoparticles with living systems depends on their char-
acteristic dimensions. Previously published studies
proved the ability of ultra small nanoparticles to translo-
cate throughout the body (see [22] and references
therein).
-Potential is the difference in the electrical charge devel-
oped between the dense layers of ions surrounding the
particles and the charge of the bulk of the suspended fluid
surrounding the particle; it gives information about the
overall surface charge of the particles [23]. Thus, the meas-
urements of -potential may indicate the colloidal stabil-
ity of nanoparticles. The interactions between the particles
play an important role in determining colloidal stability.
The use of -potential measurements to predict stability
attempts to quantify such interactions. Most nanoparti-
cles have a tendency to aggregate which may lead to pre-
cipitation that could prove dangerous if those particles are
injected intravenously. Since most aqueous colloidal sys-
tems are stabilized by electrostatic repulsion, the larger
the repulsive forces between particles, the less likely they
will come closer together and form an aggregate [24].
Therefore, it is important to know the surface charge,
which directly controls aggregation behaviour of the par-
ticles in the blood. The values of -potential for unloaded
and drug loaded nanoparticles are summarized in Table 1
which clearly indicates that loading of doxorubicin onto
nanoparticles surfaces increases positive potential of the
nanoparticles surface. The observed increase may be
explained by the fact that drug molecules bear a positive
charge and due to their loading onto the particle surface
the positive charge increases on the surface, which also
indicates towards the drug-surface interaction.
Modeling of the release mechanism
The drug loaded PHEMA nanoparticles may be visualized
as a three dimensional network of PHEMA macromole-
cules containing doxorubicin molecules, occupying the
free space available between the network chains. During
the drug release process, the drug diffuses through the
hydrated polymer matrix into the aqueous phase. The
process of hydration relaxes the polymer chains and
enhances the diffusion of drug molecules. The rate of
water uptake (hydration) of polymer particles increases
with the hydrophilicity of polymer [25]. The doxorubicin
FTIR spectra of nanoparticles Figure 2
FTIR spectra of nanoparticles. FTIR spectra of (a) Pure drug Doxorubicin and (b) Drug loaded PHEMA nanoparticles.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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molecules dissolve into water and release out through
water permeation channels present in the macromolecu-
lar network. The diffusion of doxorubicin molecules and
relaxation of PHEMA chains determine the type of release
mechanism being followed by the drug molecules.
According to Higuchi equation [26] when n = 0.43, the
release is said to be diffusion controlled (Fickian), and
when n = 0.84, the release is said to be non-Fickian (or
case II). For n being in between 0.43 and 0.84, the mech-
anism becomes anomalous. In some cases n  has been
found to exceed 0.84 and the mechanism is known as
super case II. The values of D and n are summarized in
Table 2. The data demonstrate that the value of n is lies
between 0.43 to 0.84 in the majority of cases and, there-
fore, the release of doxorubicin may be considered as non-
Fickian and swelling controlled.
Effect of % loading on drug release
An important aspect in using nanoparticles as drug vehicle
is the effect of the drug loading levels on the drug release
rates. Higher drug loading may be achieved either by
using highly concentrated drug solution or repeated soak-
ing of nanoparticles in the drug solution and then drying
them. In the present work, nanoparticles of defined com-
position were loaded with different amounts of doxoru-
bicin by allowing the particles to swell in the drug
solution of varying concentrations ranging between 1.2
and 2.4 mg/mL. The loaded particles were then allowed to
release the entrapped drug into the release medium. Drug
release results are shown in Fig. 4. The amount of released
doxorubicin increases with increasing percent loading.
Similar results were reported previously by us and others
for different drug release systems [27].
Effect of monomer on drug release
Doxorubicin release profiles are sensitive to chemical
architecture of the carrier as well as the experimental con-
ditions used to prepare the drug carrier. The effect of
HEMA on the release of doxorubicin has been investi-
gated by varying the monomer concentration in the range
12.3 mM to 24.7 mM. The swelling ratio and release
results are shown in Fig. 5(a) and 5(b). Our data indicate
that the swelling ratio and cumulative release of doxoru-
bicin decreases with increasing concentration of HEMA.
The results may be explained by the fact that as the con-
tent of PHEMA increases in the nanoparticles, the poly-
meric nanoparticles becomes largely crowded with
polymer chains and this consequently reduces the free
volume accessible to the penetrant water molecules. This
obviously brings about a fall in the swelling ratio as well
as the released amounts of drug. Another possible reason
may be that with increase in PHEMA content the interac-
tion between the polymer chains and the drug molecules
increases which also results in a lower release of doxoru-
bicin.
Effect of Cross-Linker on Drug (Doxorubicin) Release
In the cross-linked polymeric structures the swelling proc-
ess may be controlled by the introduction of an appropri-
ate amount of a second monomer with hydrophobic
SEM image and Particle Size distribution curve of nanoparti- cles Figure 3
SEM image and Particle Size distribution curve of 
nanoparticles. (a) The SEM images of cross-linked PHEMA 
nanoparticles and (b) Particle size distribution curve of cross-
linked PHEMA nanoparticles.
Table 1: Surface potential of nanoparticles
pH EMF(mV) EMF(mV) EMF(mV)
Buffer solution Unloaded Loaded
1.2 276.5 260 280.1
7.4 -34.2 -34.4 -19.9
8.6 -82.8 -86.1 -45.2
Surface potential of unloaded and loaded PHEMA nanoparticles.
*EMF data have been expressed as Mean ± S.D. of at least three 
determinations.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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character. Chemically cross-linked hydrogels have been
developed as carrier for drugs [28] in the last decade.
Cross-linkers have pronounced effect on the swelling ratio
as well as on kinetics of the drug release. We decided to
use EGDMA, which is a known hydrophobic cross-linker,
as a cross-linking agent in the present study. The effect of
the degree of cross-linking on the swelling and drug
release has been investigated by varying the concentration
of EGDMA in the range of 0.53 to 2.12 mM in the feed
mixture of the polymerization recipe. The swelling and
release results are shown in Fig. 6(a) and 6(b) respectively.
Initially the swelling ratio and drug release increase (up to
1.06 mM of EGDMA). Beyond this concentration, both
the swelling ratio and drug release decrease. The observed
increase is unusual and may be explained by loosening of
the macromolecular chains of the nanoparticles. The latter
may be due to the hydrophobic nature of EGDMA and the
hydrophobic interactions occuring along EGDMA seg-
ments. The observed decrease in the released amounts of
drug above 1.06 mM EGDMA could be because of the
reduced free volume accessible to water molecules in
more densely cross-linked polymers. Similar results have
been reported for chitosan hydrogels (by Singh et al [29]).
We showed earlier that the introduction of a cross-linker
increases the glass transition temperature (Tg) of the pol-
ymer, which restrains the mobility of network chains at
experimental temperature and, therefore, lowers both the
amount of water sorption as well as drug release [30].
Effect of initiator on drug release
In free radical polymerization the concentration of initia-
tor has a direct impact on the molecular weight of the pol-
ymer [31]. We used Bz2O2 as a polymerization initiator
and its concentration in the reaction mixture was varied in
the range of 0.082 - 0.330 mM. Swelling and release
results are depicted in Fig. 7(a) and 7(b). An initial
increase in concentration of Bz2O2 in the range of 0.082 -
0.248 mM results in an increased swelling as well as drug
release. The increase in the concentration of initiator may
bring about an increase in the number of primary free rad-
icals, which may eventually result in lower molecular
weight of the PHEMA. Since a polymer with lower molec-
ular weight has lower hydrodynamic volume in aqueous
solution, the PHEMA chains acquire greater mobility and,
therefore, show increased swelling and increased drug
release. However, the higher concentration of the initiator
Table 2: Release exponent and diffusion coefficient of nanoparticles
S.No HEMA
(mM)
EGDMA
(mM)
BPO
(mM)
pH n * Dx1015* cm2
min-1
1 12.37 1.06 0.248 7.4 0.46 ± 0.014 1.81 ± 0.054
2 16.49 1.06 0.248 7.4 0.61 ± 0.018 1.98 ± 0.059
3 20.61 1.06 0.248 7.4 0.50 ± 0.015 1.81 ± 0.054
4 24.73 1.06 0.248 7.4 0.55 ± 0.016 1.69 ± 0.051
5 12.37 0.53 0.248 7.4 0.40 ± 0.012 2.16 ± 0.065
6 12.37 1.59 0.248 7.4 0.44 ± 0.013 2.04 ± 0.061
7 12.37 2.12 0.248 7.4 0.45 ± 0.013 2.04 ± 0.061
8 12.37 1.06 0.082 7.4 0.58 ± 0.017 1.81 ± 0.054
9 12.37 1.06 0.165 7.4 0.47 ± 0.014 2.48 ± 0.074
10 12.37 1.06 0.33 7.4 0.58 ± 0.017 1.98 ± 0.059
11 12.37 1.06 0.248 1.8 0.86 ± 0.026 2.61 ± 0.078
12 12.37 1.06 0.248 8.6 0.60 ± 0.018 1.81 ± 0.054
Data showing the release exponent and diffusion coefficient under varying experimental conditions
*Data have been expressed as Mean ± S.D. of at least three determinations.
Effect of % loading of doxorubicin Figure 4
Effect of % loading of doxorubicin. Effect of % loading of 
doxorubicin on its release profiles from loaded nanoparticles 
of definite composition [HEMA] = 12.37 mM, [EGDMA] = 
1.06 mM, [Bz2O2] = 0.248 mM, pH = 7.4, temp. = 37°C.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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Effect of monomer [HEMA] Figure 5
Effect of monomer [HEMA]. Effect of monomer [HEMA] content on the (a) swelling profile and (b) release profile of the 
nanoparticles of definite composition [EGDMA] = 1.06 mM, [Bz2O2] = 0.248 mM, % loading = 28%, pH = 7.4, temp. = 37°C.
Effect of cross-linker [EGDMA] Figure 6
Effect of cross-linker [EGDMA]. Effect of cross-linker [EGDMA] content on the (a) swelling profile and (b) release profile 
of the nanoparticles of definite composition, [HEMA] = 12.37 mM, [Bz2O2] = 0.248 mM, % loading = 28%, pH = 7.4, temp. = 
37°C.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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Effect of initiator [Bz2O2] Figure 7
Effect of initiator [Bz2O2]. Effect of initiator [Bz2O2] content on the (a) swelling profile and (b) release profile of the nano-
particles of definite composition, [HEMA] = 12.37 mM, [EGDMA] = 1.06 mM, % loading = 28%, pH = 7.4, temp. = 37°C.
Effect of pH Figure 8
Effect of pH. Effect of pH on the (a) swelling profile and (b) release profile of the nanoparticles of definite composition 
[HEMA] = 12.37 mM, [EGDMA] = 1.06 mM, [Bz2O2] = 0.248 mM, % loading = 23%, temp. = 37°C.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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results in shorter PHEMA chains and smaller mesh size of
the polymer network and reduced drug loading and
release.
Effect of pH on drug release
Since the pH change occurs at many specific or physiolog-
ical sites in the body, it is one of the important parameters
in the design of drug delivery systems. Several methods
have been proposed for targeting the specific regions.
Among these, utilization of pH changes within the GI tract
and exploitation of bacterial enzymes localized within the
colon are of especial interest for the controlled drug deliv-
ery [31]. Differences in pH in the target site may allow a
specific drug to be delivered to that target site only. The
underlying principle for targeted drug delivery is the pH
controlled swelling of hydrogel which normally results
from the change in relaxation rate of network chains with
changing pH of the medium. The pH profile of normal tis-
sue is different from that of pathological tissues such as
cancerous and infected tissues. Amiji et al [32] reported
that pH of normal tissue is higher than the pH of infected
and tumourous tissues. The physical properties of stimuli-
responsive carriers such as swelling/deswelling, particles
disruption and aggregation vary according to changing
environmental conditions. These change the nanocarri-
ers-cells interactions, and therefore the release of the drug
at tumour site may be achieved. Drug loaded nanoparti-
cles undergo rapid dissolution and release the drug con-
tent in the acidic microenvironments of a tumour [33].
In the present work, the release dynamics of the doxoru-
bicin have been studied under varying pH conditions. The
results are shown in Fig. 8(a) and 8(b). We found that less
drug is released at physiological and alkaline pH, whilst
the most efficient release is achieved at acidic (pH = 1.2)
conditions. These results are not fully consistent with the
swelling results. The unloaded PHEMA nanoparticles
show maximum swelling at physiological pH solution,
whilst loaded PHEMA nanoparticles show maximum
release at acidic pH. The reason behind the lower swelling
of unloaded nanoparticles in acidic and alkaline condi-
tions is that the nanoparticles do not swell sufficiently in
acidic and alkaline solutions. Drug loaded nanoparticles
swell better in the acidic solution rather than at physiolog-
ical pH or under alkaline conditions. Similar results have
been reported recently for pH-sensitive liposomes [34].
These were stable at physiological pH of 7.4, but degraded
to release active drug in target tissues in which the pH is
less than physiologic values, such as in the acidic environ-
ment of tumour cells.
Effect of temperature on drug release
Temperature sensitivity is one of the most important char-
acteristics in drug delivery technology. It has a direct influ-
ence on the swelling and release behaviour of a hydrogel.
Temperature affects both the segmental mobility of the
hydrogel chains as well as the diffusion of penetrant mol-
ecules. In this study, the effect of temperature on the
swelling ratio and drug release through PHEMA nanopar-
ticles has been investigated by varying the temperature of
the swelling medium in the range of 12 - 37°C. The results
Effect of temperature Figure 9
Effect of temperature. Effect of temperature of the release medium on the (a) swelling profile and (b) release profile of the 
nanoparticles of definite composition [HEMA = 12.37 mM, [EGDMA] = 1.06 mM, [Bz2O2] = 0.248 mM, % loading = 28%, pH = 
7.4.Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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are summarised in Fig. 9(a) and 9(b). Swelling increased
with temperature up to 25°C, but decreased above this
temperature. However, cumulative release was highest at
37°C. The increased temperature results in faster relaxa-
tions times of the polymer network due to the increased
kinetic energy, which facilitates water sorption process
[35].
Effect of physiological fluids on drug release
The influence of solutes on the swelling behaviour and
doxorubicin release kinetics was examined by performing
swelling and release experiments in the presence of sol-
utes such as urea (15% w/v) and D-glucose (5% w/v) and
in physiological fluids such as saline water (0.9% NaCl)
and synthetic urine. The results are shown in Fig. 10(a)
and 10(b). The presence of additives reduces both the
swelling ratio as well as drug release. Salts present in the
release medium are likely to reduce the osmotic pressure
in the system thus resulting in lower extent of swelling of
loaded nanoparticles and the drug release.
Chemical stability of the entrapped doxorubicin
The chemical stability of the entrapped drug was investi-
gated by recording the UV-visible absorbance spectra of
pure doxorubicin and the drug released into the release
medium at different pH (fig. 11). There are no noticeable
differences in the obtained absorbance spectra at all pH
tested (pH1.8, pH7.4, pH8.6), suggesting no significant
changes in the physical properties of the drug, and most
likely of its chemical structure during nanoparticle load-
ing and drug release.
Conclusion
The PHEMA nanoparticles can be prepared by suspension
polymerization method and characterized by techniques
such as FTIR, SEM and particle size analysis. The addition
of model drug, doxorubicin, to polymeric nanoparticles
results in 28% drug entrapment. Release profiles of doxo-
rubicin can be greatly modified by varying the experimen-
Effect of physiological fluids Figure 10
Effect of physiological fluids. Effect of physiological fluids on the (a) swelling profile and (b) release profile of the nanoparti-
cles of definite composition [HEMA] = 12.37 mM, [EGDMA] = 1.06 mM, [Bz2O2] = 0.248 mM, % loading = 28%, pH = 7.4, 
temp. = 37°C.
Chemical stability of Doxorubicin Figure 11
Chemical stability of Doxorubicin. UV spectra showing 
the chemical stability of doxorubicin in its pure solution (a) 
and released media (b) at different pH (1.8, 7.4, 8.6).Journal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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tal parameters such as percent loading of doxorubicin and
concentrations of HEMA, cross-linker and initiator. Swell-
ing of nanoparticles and the release of doxorubicin
increases with the increase in percentage loading of drug.
The amount of released drug decreases with increasing
HEMA and EGDMA content of the nanoparticles. Increase
in the concentration of the initiator, benzoyl peroxide,
from 0.082 mM to 0.248 mM results in the increase of
drug release, but this effect is reduced at higher concetra-
tion of benzoyl peroxide. The best combination of indi-
vidual components for making PHEMA nanoparticles for
doxorubicin delivery was 12.37 mM HEMA, 1.06 mM
EGDMA and 0.248 mM Bz2O2. Fast drug release was
observed at acidic pH1.2 at 37°C whilst physiological and
alkaline pH and lower temperature slow down the release
of doxorubicin. alts and additives affecting osmotic pres-
sure also suppress the extent of drug release. Absorption
spectra of doxorubicin do not change following its cap-
ture and release form the nanoparticles, indicating that
chemical structure of the drug is likely to be unaffected by
the procedure.
Methods
Materials
2-Hydroxyethyl methacrylate (HEMA) and ethyleneglycol
dimethacrylate (EGDMA) were purchased from Sigma
Aldrich Co. USA. Benzoyl peroxide (BPO) (MERCK) and
polyvinyl alcohol (PVA) (Mol. Wt. 14000) (MERCK) were
used as the initiator and the stabilizer, respectively. Tolu-
ene (MERCK) was used as the diluent. All chemicals were
of analytical grade and doubly distilled water was used
throughout the experiments.
Methods
HEMA monomer was purified by using a previously
reported method [30]. The purity of distilled HEMA was
determined by high-pressure liquid chromatography
(HPLC), [Backmen System (Gold 127)] equipped with a
ultraviolet detector and a 25 cm × 46 mm id separation
columns ODS (C18) of 5 m particle size. The UV detector
was set at 217 nm. The mobile phase was methanol-water
(60:40 v/v) and the flow-rate was kept at 1 mL/min. All
samples were diluted with pure methanol to 1/1600. 10
L samples were injected for each analysis. Samples of
known concentrations of MAA and EGDMA were injected
into the HPLC and the resultant chromatogram was used
to construct a standard curve of known concentrations vs.
area under the curve. The chromatogram showed two dis-
tinct peaks. The first peak, at 3.614 min was identified as
MAA. The next peak at 5.503 min was the major peak due
to HEMA monomer. The amounts of impurities of MAA
and EGDMA in the monomer samples were found to be
less than 0.01 mol% MAA and 0.001 mol% EGDMA.
Preparative methods for making nanoparticles for phar-
maceutical use are broadly divided into two categories,
those based on physiochemical properties such as phase
separation and solvent evaporation [36], and chemical
reactions such as polymerization [37], and polycondensa-
tion. In the present study cross-linked PHEMA nanoparti-
cles of defined composition were prepared by using a
modified suspension polymerization technique, as previ-
ously reported by Kaparissides et. al. [38]. In particular, the
polymerization was carried out in an aqueous phase con-
taining PVA, which was used as the stabilizing agent. The
mixture containing the 12.37 mM HEMA (the monomer),
1.06 mM EGDMA (the cross-linker) and 0.248 mM Bz2O2
(the initiator) dispersed in toluene was added into 500
mL conical flask containing the suspension medium (200
mL aqueous PVA solution (0.5% W/V)). The reaction mix-
ture was flushed by bubbling nitrogen and then sealed.
The reaction mixture was then placed on magnetic stirrer
and heated by vigorous stirring (600-700 rpm) at 80°C
for 2 h and then at 90°C for 1 h. The cross-linking reaction
was completed within three hours. After cooling, the pol-
ymeric particles were separated from the polymerization
medium by washing thrice with toluene and twice with
acetone. The collected nanoparticles were dried at room
temperature to obtain the fine white powder and thereaf-
ter stored in airtight polyethylene bags.
The IR spectra of cross-linked PHEMA nanoparticles were
recorded on a FTIR spectrophotometer (Perkin-Elmer,
1000 Paragon) (Shimadzu). While recording FTIR spectra
KBr disc method was used for preparation of samples.
Morphological studies of cross-linked PHEMA nanoparti-
cles were performed on scanning electron micrographs
(SEM). SEM observations were carried out with a Philips,
515, fine coater. Drops of the polymeric nanoparticles
suspension were placed on a graphite surface and freeze
dried. The sample was then coated with gold by ion sput-
ter. The coating was performed at 20 mA for 4 min, and
observation was made at 10 KV. Nanoparticles were fur-
ther characterized by particle size analysis for size and size
distribution. The particle size analysis of prepared nano-
particles was performed on a particle size analyzer (Mal-
vern Mastersizer 2000).
Zeta potential studies were performed with a digital
potentiometer (Model No. 118, EI Product, Mumbai,
India). In a typical experiment 0.1 g nanoparticles were
dispersed in 20 mL of respective pH solution and emf was
recorded using a compound electrode system. A similar
experiment was also repeated for drug-loaded nanoparti-
cles.
Swelling properties of hydrogels can be used as a method
to trigger drug release [39]. Swelling of nanoparticles wasJournal of Nanobiotechnology 2009, 7:5 http://www.jnanobiotechnology.com/content/7/1/5
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studied by a conventional gravimetric procedure. In a typ-
ical experiment, 0.1 g of nanoparticles were allowed to
swell in a definite volume (10 mL) of PBS taken in a pre
weighed sintered glass crucible (pore size 5-10 m) and
weighed after a definite period by removing excess PBS by
vacuum filtration. The swelling process of nanoparticles
was monitored continuously up to 15 min after which no
weight gain of swollen nanoparticles was recorded which
clearly indicates equilibrium swelling condition. The
weight swelling ratio of nanoparticles was calculated from
the following equation,
where, Wt is the weight of swollen nanoparticles at time t,
and W0 is the initial weight of dry nanoparticles (at time
0).
For loading of drugs onto nanoparticles, a known volume
of drug doxorubicin was taken and diluted with the
appropriate amount of PBS solution and shaken vigor-
ously for mixing of drug and PBS solution. Drug-loaded
nanoparticles were prepared by swelling 0.1 g of nanopar-
ticles in freshly prepared drug solution (10 mL) until
equilibrium swelling was reached. The % loading of drug
onto nanoparticles was calculated by the following equa-
tion:
where, Wd and W0 are the weights of loaded and unloaded
nanoparticles, respectively.
In-vitro release of the loaded doxorubicin was carried out
by placing the dried and loaded nanoparticles (0.1 g) in a
test tube containing a definite volume (10 mL) of phos-
phate buffer saline (PBS) as the release medium (pH =
7.4) (1.2 mM KH2PO4, 1.15 mM Na2HPO4, 2.7 mM KCl,
1.38 mM NaCl). The amount of doxorubicin released
from the polymeric nanoparticles was measured spectro-
photometrically at 496 nm (Shimandzu 1700 Phama
Spec.) and the released amount of drug was determined
from the calibration plot.
To study the kinetics of the release process, drug-loaded
nanoparticles were added to the release medium and the
suspension was shaken for 3.5 h. For monitoring the
progress of the release process, aliquots were withdrawn at
desired time intervals and the amount of drug released
was estimated spectrophotometrically.
The drug release from polymeric nanoparticulate systems
is actually the combination of Fickian (diffusion) and
non-Fickian movements [40] of drug molecules through
polymer chains. In the present study the kinetic data were
analyzed with the help of the following equation, which
could be helpful in determining the mechanism of the
release process,
where Wt and W are the amount of the drug release at
time t and at infinity time (equilibrium amount of drug
released), respectively, and K is rate constant. The con-
stants K and n are characteristics of the drug-polymer sys-
tem. An introduction to the use and the limitations of
these equations was fist given by Peppas et al. [41]. For
evaluating the diffusion constant of loaded drugs, the fol-
lowing equation can be used:
where, D is the diffusion constant of the drug and L being
the diameter of the dry nanoparticles.
In order to check the chemical stability of entrapped drug
in different release media, the UV spectral studies (Shi-
mandzu 1700 Pharma Spec) were performed as described
in [42].
All experiments were done at least thrice and a fair repro-
ducibility was observed. The data summarized in Tables
have been expressed as mean ± SD of at least three inde-
pendent determinations. The plots were drawn taking the
mean values and each curve has been shown to include
error bars.
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